SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Information Analysis (OTCMKTS:IAIC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares SOPHiA GENETICS and Information Analysis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -93.86% | -132.47% | -45.97% |
| Information Analysis | 3.72% | 18.48% | 9.33% |
Risk and Volatility
SOPHiA GENETICS has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Information Analysis has a beta of 3.25, indicating that its stock price is 225% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $77.27 million | 9.21 | -$79.00 million | ($1.15) | -7.37 |
| Information Analysis | $13.90 million | 0.00 | $410,000.00 | $0.04 | N/A |
Information Analysis has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Information Analysis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for SOPHiA GENETICS and Information Analysis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
| Information Analysis | 0 | 0 | 0 | 0 | 0.00 |
SOPHiA GENETICS presently has a consensus price target of $10.00, indicating a potential upside of 17.92%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than Information Analysis.
Institutional & Insider Ownership
31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 23.8% of Information Analysis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Information Analysis beats SOPHiA GENETICS on 8 of the 13 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About Information Analysis
Information Analysis, Inc. provides information technology services. The firm engages in the business of modernizing client information systems, developing and maintaining information technology systems, and performing consulting services to government and commercial organizations. It specializes in legacy systems modernization, ebusiness solutions, enterprise portals, system migration and re-hosting services, and enterprise application integration. The company was founded by Sandor Rosenberg in 1979 and is headquartered in Fairfax, VA.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
